Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Balazs Halmos

Showing results (61-70 of 221) with videos related to

Pageof 23
Sort By:
Cancers|December 9, 2020
A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLCBalazs Halmos, Thomas Burke, Chrysostomos Kalyvas, et al.
Immunotherapy|January 25, 2022
Indirect comparison of pembrolizumab monotherapy versus nivolumab + ipilimumab in first-line metastatic lung cancerBalazs Halmos, Thomas Burke, Chrysostomos Kalyvas, et al.
Frontiers in Oncology|May 3, 2024
Real-world outcomes on platinum-containing chemotherapy for <i>EGFR</i>-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitorsBalazs Halmos, Pragya Rai, Jae Min, et al.
Journal of the American Academy of Dermatology|June 13, 2026
Considerations for Commonly Prescribed Medications by Dermatologists in Patients on Immune Checkpoint InhibitorsCarolyn Rachofsky, Mei Hong Liu, Angelica D'Aiello, et al.
International Journal of Cancer|July 2, 2009
Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancerAmy Kluge, Snehal Dabir, Jeffrey Kern, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 29, 2016
Marked Differences in CNS Activity among EGFR Inhibitors: Case Report and Mini-ReviewVipul Pareek, Mary Welch, Elizabeth Ravera, et al.
Oncotarget|June 5, 2018
PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signalingXiaoqi Wang, Guangyuan Li, Sanjay Koul, et al.
Journal of Gastrointestinal Cancer|May 16, 2012
Management of Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy in a Patient with Scleroderma: Case Report and Review of the LiteratureDavid P Horowitz, Balazs Halmos, John Poneros, et al.
Journal of Gastrointestinal Cancer|January 14, 2014
Complete pathological response in a patient with metastatic esophageal cancer treated with a regimen of capecitabine, oxaliplatin and docetaxel: a case reportNagashree Seetharamu, Jonathan Melamed, George Miller, et al.
Cancer Biology & Therapy|May 20, 2014
Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinibYuxia Jia, Siraj M Ali, Shumaila Saad, et al.
Pageof 23

Showing results (61-70 of 221) with videos related to

Sort By:
Pageof 23
Cancers|December 9, 2020
A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLCBalazs Halmos, Thomas Burke, Chrysostomos Kalyvas, et al.
Immunotherapy|January 25, 2022
Indirect comparison of pembrolizumab monotherapy versus nivolumab + ipilimumab in first-line metastatic lung cancerBalazs Halmos, Thomas Burke, Chrysostomos Kalyvas, et al.
Frontiers in Oncology|May 3, 2024
Real-world outcomes on platinum-containing chemotherapy for <i>EGFR</i>-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitorsBalazs Halmos, Pragya Rai, Jae Min, et al.
Journal of the American Academy of Dermatology|June 13, 2026
Considerations for Commonly Prescribed Medications by Dermatologists in Patients on Immune Checkpoint InhibitorsCarolyn Rachofsky, Mei Hong Liu, Angelica D'Aiello, et al.
International Journal of Cancer|July 2, 2009
Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancerAmy Kluge, Snehal Dabir, Jeffrey Kern, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 29, 2016
Marked Differences in CNS Activity among EGFR Inhibitors: Case Report and Mini-ReviewVipul Pareek, Mary Welch, Elizabeth Ravera, et al.
Oncotarget|June 5, 2018
PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signalingXiaoqi Wang, Guangyuan Li, Sanjay Koul, et al.
Journal of Gastrointestinal Cancer|May 16, 2012
Management of Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy in a Patient with Scleroderma: Case Report and Review of the LiteratureDavid P Horowitz, Balazs Halmos, John Poneros, et al.
Journal of Gastrointestinal Cancer|January 14, 2014
Complete pathological response in a patient with metastatic esophageal cancer treated with a regimen of capecitabine, oxaliplatin and docetaxel: a case reportNagashree Seetharamu, Jonathan Melamed, George Miller, et al.
Cancer Biology & Therapy|May 20, 2014
Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinibYuxia Jia, Siraj M Ali, Shumaila Saad, et al.
Pageof 23